<DOC>
	<DOCNO>NCT01094990</DOCNO>
	<brief_summary>Null hypothesis The proportion vomit different dexamethasone placebo patient sedation intravenous ketamine lumbar puncture intrathecal chemotherapy Alternative hypothesis The proportion vomit different dexamethasone placebo patient sedation intravenous ketamine lumbar puncture intrathecal chemotherapy</brief_summary>
	<brief_title>Efficacy Dexamethasone Prevent Vomiting Leukemic Children Who Receive Intrathecal Chemotherapy</brief_title>
	<detailed_description>Does intravenous dexamethasone 0.25 mg/kg ( 8 mg/m2/dose ) effect reduction vomit retch sedation intravenous ketamine lumbar puncture intrathecal chemotherapy comparison placebo ?</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Patients age 215 year underlie acute lymphoid nonlymphoid leukemia need receive ketamine intrathecal chemotherapy . Personally sign date informed consent assent document indicate subject ( legally acceptable representative ) inform pertinent aspect trial prior study entry . Patients know allergy ketamine dexamethasone . Patients contraindication ketamine dexemethasone hypertension , increase intracranial pressure central nervous system mass lesion , major psychiatric , hyperglycemia . Patients concurrent nausea vomit time . Patients receive ondansetron antiemetic Procedure . Patients receive chemotherapy 24 hour .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>crossover ; double blind ; intrathecal chemotherapy ; dexamethasone ; ketamine ; vomit</keyword>
</DOC>